Home Abstract

Preparation and Evaluation of Bendamustine Hydrochloride Non Aqueous Formulations

Received On: 10/05/2013
Accepted On: 22/05/2013


Prasanna, S., Puranik, S. B.

Author's Affiliation


B-cell chronic lymphocytic leukemia (B-CLL), also known as chronic lymphoid leukemia (CLL), is the most common type of leukemia. Leukemias are cancers of the white blood cells (leukocytes). CLL affects B cell lymphocytes. B cells originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. Bendamustine (INN, trade names Ribomustin and Treanda; also known as SDX-105) is a nitrogen mustard used in the treatment of chronic lymphocytic leukemias (CLL) and lymphomas. It belongs to the family of drugs called alkylating agents. It is also being studied for the treatment of sarcoma1. Bendamustine Hydrochloride is commercially available in the market as lyophilizzed dosage form. Also enough literature is available that Bendamustine Hydrochloride is very unstable in the liquid dosage form. It undergoes hydrolytic degradation in the presence of water2. Hence an attempt for developing a simple, aqueous and non aqueous based Bendamustine Hydrochloride formulations have been attempted.


Bendamsutine Hydrochloride, Dimethylacetamide, Polyethylene glycol 300, Propylene glycol

Cite This Article

Prasanna, S., Puranik, S. B. (2013). Preparation and Evaluation of Bendamustine Hydrochloride Non Aqueous Formulations. International Journal for Pharmaceutical Research Scholars (IJPRS), 2(2), 136-139.

Recent Articles

Get FREE Updates for Upcoming
Pharma News, Jobs & Conferences

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

IJPRS will use the information you provide on this form to be in touch with you and to provide updates and marketing.